Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taurine Combined With Serplulimab and Chemotherapy in Locally Advanced Gastric Cancer
NCT06128252Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Sep 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in gastric cancer (GC) and gastroesophageal junction adenocarcinoma comparing Taurine + Serplulimab + XELOX with Placebo + Serplulimab + XELOX (2 arms). Primary endpoint: Pathological Complete Response. Started Sep 2024; status: recruiting.
02
Drugs
taurine
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06128252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128252.